ZANGANEH MAHKAM purchased 53.4% of their position (26.68K shares) of SUMMIT THERAPEUTICS INC. on the open market
Open‑market purchase worth $500.0K — a major conviction buy. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 10/23/2025ACC: 0001507650-25-000003
+14.27M
Net shares
Net buyer
$267.50M
Total acquired
1
Open market trades
1B · 0S
3
Total transactions
14.27M acquired
Non-Derivative Transactions3
Common Stock
Indirect
Shares
+266.81K
Price / share
$18.74
Trade value
$5M
% of position
1.0%
10/21/2025
25.46M→25.72M
Common Stock
Indirect
Shares
+26.68K
Price / share
$18.74
Trade value
$499.98K
% of position
53.4%
10/21/2025
50K→76.68K
Common Stock
Indirect
Shares
+13.98M
Price / share
$18.74
Trade value
$262M
% of position
2.5%
10/21/2025
556.09M→570.07M
Total
Net shares
+14.27M
Net value
$267.50M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 10/21/2025 | A · Award | +266.81K | $18.74 | $5M | 1.0% | 25.46M | 25.72M |
| Common Stock Indirect | 10/21/2025 | P · Purchase | +26.68K | $18.74 | $499.98K | 53.4% | 50K | 76.68K |
| Common Stock Indirect | 10/21/2025 | A · Award | +13.98M | $18.74 | $262M | 2.5% | 556.09M | 570.07M |
| Total | +14.27M | $267.50M | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)2
Common Stock
IndirectShares owned10.20M
Common Stock
DirectShares owned31K
Total
31K direct·10.20M indirect10.23M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 10.20M | Indirect |
| Common Stock | 31K | Direct |
| Total | 10.23M | 31K direct·10.20M indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported